Sugi Predict

Sugi Predict / Compounds / SCHEMBL5857601

SCHEMBL5857601

SCHEMBL5857601

Cc1[nH]c2ccc(F)cc2c1C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KEAP1 Q14145 1/20 0.50
▸ NFE2L2 Q16236 1/20 0.50
▸ KDM4E B2RXH2 3/20 0.49
▸ ALDH1A1 P00352 2/20 0.49
▸ HPGD P15428 2/20 0.49
▸ THRB P10828 1/20 0.49
▸ LMNA P02545 3/20 0.46
▸ KIF11 P52732 1/20 0.46
▸ PDPK1 O15530 1/20 0.46
▸ TSHR P16473 1/20 0.46
▸ NFKB1 P19838 1/20 0.46
▸ APEX1 P27695 1/20 0.46
▸ CYP2C19 P33261 1/20 0.46
▸ HSD17B10 Q99714 1/20 0.46
▸ TDP1 Q9NUW8 1/20 0.46
▸ GAA P10253 1/20 0.46
▸ TUBB4A P04350 1/20 0.45
▸ TUBB P07437 1/20 0.45
▸ TUBA3C P0DPH7 1/20 0.45
▸ TUBA1B P68363 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25169884 0.87 PTGS1 (0.55) KDM4EALDH1A1HPGDLMNAKIF11
SCHEMBL21809222 0.87 KEAP1 (0.50) KEAP1NFE2L2KDM4EALDH1A1LMNA
SCHEMBL3628074 0.85 MAP2 (0.50) KEAP1NFE2L2LMNAKIF11GAA
SCHEMBL18932673 0.83 ALDH1A1 (0.59) KDM4EALDH1A1HPGDTHRBHSD17B10
SCHEMBL6877031 0.83 KEAP1 (0.46) KEAP1NFE2L2KDM4EALDH1A1LMNA
SCHEMBL5236009 0.83 NR4A2 (0.63) KEAP1NFE2L2KDM4EALDH1A1HPGD
SCHEMBL8889498 0.83 KEAP1 (0.50) KEAP1NFE2L2KDM4EALDH1A1HPGD
SCHEMBL15545957 0.81 PTGS2 (0.45) KEAP1NFE2L2KDM4EALDH1A1HPGD
SCHEMBL14265135 0.81 MAPT (0.50) KEAP1NFE2L2KDM4EALDH1A1HPGD
SCHEMBL3385819 0.81 GAA (0.66) KDM4EALDH1A1HPGDTHRBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11891386-B2 Indole compounds and their use ARIAGEN, INC. (CA) 2024-02-06 — — US disclosed
US-20230145074-A1 Indole Compounds and Their Use ARIAGEN, INC. (US) 2023-05-11 — — US disclosed
US-20230145074-A1 Indole Compounds and Their Use ARIAGEN, INC. (US) 2023-05-11 — — US disclosed
US-20230145074-A1 Indole Compounds and Their Use ARIAGEN, INC. (US) 2023-05-11 — — US disclosed
US-20230054194-A1 Methods of Treating Cancer ARIAGEN, INC. (US) 2023-02-23 — — US disclosed
US-20230054194-A1 Methods of Treating Cancer ARIAGEN, INC. (US) 2023-02-23 — — US disclosed
US-11459322-B2 Indole compounds and their use ARIAGEN, INC. (US) 2022-10-04 — — US disclosed
US-11459322-B2 Indole compounds and their use ARIAGEN, INC. (US) 2022-10-04 — — US disclosed
US-11427576-B2 Indole compounds and their use ARIAGEN, INC. (US) 2022-08-30 — — US disclosed
EP-3883605-A1 METHODS OF TREATING CANCER Ariagen, Inc. (US) 2021-09-29 — — EP disclosed
CN-111587249-A Indole compounds and uses thereof 阿里根公司 2020-08-25 — — CN disclosed
US-7112594-B2 Fused bicyclic amide compounds and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2006-09-26 — — US disclosed
US-20030203909-A1 Fused bicyclic amide compounds and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2003-10-30 — — US disclosed
EP-1310488-A1 FUSED BICYCLIC AMIDE COMPOUNDS AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2003-05-14 — — EP disclosed
EP-0150505-B1 3-INDOLECARBOXAMIDE COMPOUNDS Yoshitomi Pharmaceutical Industries, Ltd. (JP) 1987-04-01 — — EP disclosed
EP-0144986-B1 INDOLE-3-CARBOXAMIDE DERIVATIVES Yoshitomi Pharmaceutical Industries, Ltd. (JP) 1987-03-04 — — EP disclosed
US-4616009-A PSYCHOLOGICAL DISORDERS YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 1986-10-07 — — US disclosed
US-4581355-A HYPOTENSIVE AGENTS, LIPOXYGENASE INHIBITORS YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 1986-04-08 — — US disclosed
EP-0150505-A2 3-Indolecarboxamide compounds Yoshitomi Pharmaceutical Industries, Ltd. (JP) 1985-08-07 — — EP disclosed
EP-0144986-A2 Indole-3-carboxamide derivatives Yoshitomi Pharmaceutical Industries, Ltd. (JP) 1985-06-19 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030203909-A1 Fused bicyclic amide compounds and medicinal use thereof BET1, NFATC1, ARG1 KEAP1 1976/4885NFE2L2 937/4885KDM4E 474/4885
US-11459322-B2 Indole compounds and their use IDO1, IDO2, INMT KEAP1 461/4885NFE2L2 236/4885KDM4E 1007/4885
US-11427576-B2 Indole compounds and their use IDO1, IDO2, INMT KEAP1 461/4885NFE2L2 236/4885KDM4E 1007/4885
US-11891386-B2 Indole compounds and their use IDO1, IDO2, INMT KEAP1 461/4885NFE2L2 236/4885KDM4E 1007/4885
US-20230054194-A1 Methods of Treating Cancer TP53, MSH2, PDCD1 KEAP1 791/4885NFE2L2 1182/4885KDM4E 1153/4885
US-20230145074-A1 Indole Compounds and Their Use IDO1, IDO2, INMT KEAP1 461/4885NFE2L2 236/4885KDM4E 1007/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.